Patent intelligence · US
US 9351997
Method of treating cancer
Method of treating cancer
Patent details — US 9351997
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 31, 2016
- Expiration
- May 26, 2036
- Applicant
- Intensity Therapeutics, Inc.
- Claims
- 3
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524
Quick answer
US 9351997 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Intensity Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2800/30, A61K2800/34, A61K2800/524, A61K31/192, A61K31/20
More from Intensity Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 9351997?
US 9351997 (Method of treating cancer) is held by Intensity Therapeutics, Inc.. Status: granted. Granted May 31, 2016. Expires May 26, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9351997?
Intensity Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 9351997 expire?
Our index shows an expiration date of May 26, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.